Skip to main content

Master Protocol Development: COVID-19 Natural History

    Basic Details
    Date Posted
    Status
    Complete
    Health Outcome(s)
    COVID-19
    Description

    The COVID-19 Natural History Master Protocol effort involves the development of a protocol designed to identify multiple COVID-19 cohorts to support a variety of on-demand queries and subsequent inferential studies. The protocol will be adaptable to various data sources with clinically rich data and will include specific populations of interest, such as the pediatric population, pregnant women, and other vulnerable populations identified by FDA. The implementation of the Natural History protocol will prioritize data source capabilities, such as: a) the capacity to form stable population-based cohorts that can be refreshed quickly and reliably over time, b) deep on-site pharmacoepidemiology experience with a research record of both descriptive and inferential studies, and c) demonstrated analytic capability to support rapid on-demand queries which support identification of the natural history of COVID-19. Expert infectious disease specialists and pharmacoepidemiologists will lead development of this protocol and its implementation in various data sources in the Sentinel network.

    Information
    Time Period
    June 2020 - August 2020
    Population / Cohort
    All individuals
    Data Source(s)
    Select Data Partners
    Workgroup Leader(s)

    Wei Hua, MD, PhD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Katherine Yih, PhD, MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

    Vincent Lo Re, MD, MSCE; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania

    Workgroup Member(s)

    Michael Nguyen, MD; Robert Ball, MD, MPH, ScM; Brian Kit, MD, MPH; Sarah Dutcher, PhD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Darren Toh, ScD; Meighan Rogers Driscoll, MPH; Candace Fuller, PhD, MPH; Maria Kempner, MPH; Christine Draper; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA